Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701

被引：0

作者：

Tomono Kawase

Hiroshi Imamura

Masahiro Goto

Yutaka Kimura

Shugo Ueda

Jin Matsuyama

Kazuhiro Nishikawa

Naotoshi Sugimoto

Junya Fujita

Takao Tamura

Norimasa Fukushima

Hisato Kawakami

Daisuke Sakai

Yukinori Kurokawa

Toshio Shimokawa

Taroh Satoh

机构：

[1] Toyonaka Municipal Hospital,Department of Surgery

[2] Osaka Medical College Hospital,Cancer Chemotherapy Center

[3] Kinki University,Department of Surgery, Faculty of Medicine

[4] Kitano Hospital,Department of Gastroenterological Surgery

[5] Higashiosaka City Medical Center,Department of Gastroenterological Surgery

[6] Osaka General Medical Center,Department of Surgery

[7] Osaka International Cancer Institute,Department of Medical Oncology

[8] Sakai City Medical Center,Department of Surgery

[9] Kindai University,Department of Medical Oncology, Faculty of Medicine

[10] Yamagata Prefectural Central Hospital,Department of Surgery

[11] Osaka University Graduate School of Medicine,Department of Frontier Science for Cancer and Chemotherapy

[12] Osaka University Graduate School of Medicine,Department of Gastroenterological Surgery

[13] Wakayama Medical University,Clinical Study Support Center

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Gastric cancer; Second-line chemotherapy; Paclitaxel; Irinotecan; S-1;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1871 / 1880

页数：9

共 50 条

[31] S-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer
Nagahashi, S
Suzuki, H
Hibi, T
PROCEEDINGS OF THE 6TH INTERNATIONAL GASTRIC CANCER CONGRESS, 2005, : 155 - 161
[32] A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer
Michiya Kobayashi
Akira Tsuburaya
Naoki Nagata
Yumi Miyashita
Koji Oba
Junichi Sakamoto
Gastric Cancer, 2006, 9 (2) : 114 - 119
[33] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
Mizuno, Nobumasa
Yamao, Kenji
Komatsu, Yoshito
Munakata, Masaki
Ishiguro, Atsushi
Yamaguchi, Taketo
Ohkawa, Shinichi
Kida, Mitsuhiro
Ioka, Tatsuya
Takeda, Koji
Kudo, Toshihiro
Kitano, Masayuki
Iguchi, Haruo
Tsuji, Akihito
Ito, Tetsuhide
Tanaka, Masao
Furuse, Junji
Hamada, Chikuma
Sakata, Yuh
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[34] Adjuvant chemotherapy of S-1 versus S-1 plus metformin for resected pancreatic cancer: A multicenter and randomized phase II trial.
Narita, Masato
Furukawa, Masayuki
Sakamoto, Ichiro
Itoh, Yutaka
Nakano, Hiroshi
Naka, Takuji
Sudo, Takeshi
Yahara, Noboru
Aoki, Hideki
Oota, Kouji
Matsumoto, Toshifumi
Shimokawa, Mototsugu
Hisano, Terumasa
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[35] Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)
Yoshino, Shigefumi
Nishikawa, Kazuhiro
Morita, Satoshi
Takahashi, Tsuyoshi
Sakata, Koichiro
Nagao, Jiro
Nemoto, Hiroshi
Murakami, Nozomu
Matsuda, Takeru
Hasegawa, Hiroyasu
Shimizu, Ryoichi
Yoshikawa, Takaki
Osanai, Hiroyuki
Imano, Motohiro
Naitoh, Hiroshi
Tanaka, Akiyoshi
Tajiri, Takashi
Gochi, Akira
Suzuki, Michinari
Sakamoto, Junichi
Saji, Shigetoyo
Oka, Masaaki
EUROPEAN JOURNAL OF CANCER, 2016, 65 : 164 - 171
[36] Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC)
Okusaka, T.
Ueno, M.
Omuro, Y.
Isayama, H.
Fukutomi, A.
Ikeda, M.
Mizuno, N.
Fukuzawa, K.
Hyodo, I.
Boku, N.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611
[37] S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
Hironaka, Shuichi
Sugimoto, Naotoshi
Yamaguchi, Kensei
Moriwaki, Toshikazu
Komatsu, Yoshito
Nishina, Tomohiro
Tsuji, Akihito
Nakajima, Takako Eguchi
Gotoh, Masahiro
Machida, Nozomu
Bando, Hideaki
Esaki, Taito
Emi, Yasunori
Sekikawa, Takashi
Matsumoto, Shigemi
Takeuchi, Masahiro
Boku, Narikazu
Baba, Hideo
Hyodo, Ichinosuke
LANCET ONCOLOGY, 2016, 17 (01): : 99 - 108
[38] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
Kang, Yoon-Koo
Yook, Jeong Hwan
Park, Young-Kyu
Lee, Jong Seok
Kim, Young-Woo
Kim, Jin Young
Ryu, Min-Hee
Rha, Sun Young
Chung, Ik Joo
Kim, In-Ho
Oh, Sang Cheul
Park, Young Soo
Son, Taeil
Jung, Mi Ran
Heo, Mi Hwa
Kim, Hark Kyun
Park, ChoHyun
Yoo, Chang Hak
Choi, Jin-Hyuk
Zang, Dae Young
Jang, You Jin
Sul, Ji Young
Kim, Jong Gwang
Kim, Beom Su
Beom, Seung-Hoon
Cho, Sang Hee
Ryu, Seung Wan
Kook, Myeong-Cherl
Ryoo, Baek-Yeol
Kim, Hyun Ki
Yoo, Moon-Won
Lee, Nam Su
Lee, Sang Ho
Kim, Gyunji
Lee, YeonJu
Lee, Jee Hyun
Noh, Sung Hoon
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2903 - +
[39] Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial
Kim, Y. H.
Koizumi, W.
Lee, K. H.
Kishimoto, T.
Chung, H. C.
Hara, T.
Cho, J. Y.
Nakajima, T.
Kim, H.
Fujii, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[40] Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer
Hosokawa, Ayumu
Ando, Takayuki
Ogawa, Kohei
Ueda, Akira
Yoshita, Hiroki
Mihara, Hiroshi
Fujinami, Haruka
Kajiura, Shinya
Yabushita, Kazuhisa
Horikawa, Naoki
Kobayashi, Yuka
Yoshioka, Akira
Origasa, Hideki
Sugiyama, Toshiro
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (10): : 977 - 981

← 1 2 3 4 5 →